Changes in mucociliary clearance over time in children with cystic fibrosis.


Journal

Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590

Informations de publication

Date de publication:
09 2020
Historique:
received: 26 12 2019
accepted: 17 05 2020
pubmed: 20 5 2020
medline: 12 1 2021
entrez: 20 5 2020
Statut: ppublish

Résumé

(a) To quantify changes in mucociliary clearance (MCC) over time in children with cystic fibrosis (CF) and the relationship between MCC and rate of infection with Pseudomonas aeruginosa (PA); (b) to determine the impact of MCC on the evolution of CF lung disease; and (c) to explore the role of mucus composition as a determinant of MCC. Children with CF, who had previously undergone an MCC measurement (visit 1), underwent the following tests 3 to 10 years later: (a) second MCC measurement (visit 2); (b) multiple breath washout to assess ventilation inhomogeneity, expressed as lung clearance index (LCI); (c) high resolution computed tomography lung scan (HRCT); and (d) induced sputum test. Number of PA + cultures/year between visits was documented and mucus dry weight was quantified in the children and adult controls. Nineteen children completed both visits. Median time between visits was 4.6 years. Clearance declined 30% between visits. Lower MCC on visit 2 was associated with more PA+ cultures/year between visits. Lower MCC values on visit 1 were associated with higher LCI values and higher HRCT scores on visit 2. Mucus dry weight was significantly higher in children with CF compared with controls. Higher dry weights were associated with lower MCC. Mucociliary clearance declines significantly over time in children with CF. The decline is associated with PA infection rate and is affected by mucus composition. Children with early slowing of MCC appear to be at risk for developing ventilation inhomogeneity and parenchymal lung damage when they are older.

Identifiants

pubmed: 32427408
doi: 10.1002/ppul.24858
pmc: PMC7674244
mid: NIHMS1605971
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2307-2314

Subventions

Organisme : NIH HHS
ID : R01 HL129925
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001079
Pays : United States
Organisme : NIH HHS
ID : UL1 TR001079
Pays : United States
Organisme : NIH HHS
ID : R01 HL080396
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL080396
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL130938
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003098
Pays : United States
Organisme : NIH HHS
ID : R01 HL130938
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL129925
Pays : United States

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Eur Respir J. 2013 Mar;41(3):507-22
pubmed: 23397305
Am J Physiol Lung Cell Mol Physiol. 2016 May 1;310(9):L860-7
pubmed: 26968767
J Clin Invest. 2014 Jul;124(7):3047-60
pubmed: 24892808
J Immunol. 2005 Jul 15;175(2):1090-9
pubmed: 16002710
Thorax. 2008 Feb;63(2):96-7
pubmed: 18234652
Am J Respir Crit Care Med. 2005 Feb 15;171(4):371-8
pubmed: 15531750
Pediatr Radiol. 2014 Dec;44(12):1496-506
pubmed: 25164326
Proc Am Thorac Soc. 2007 Aug 1;4(4):399-405
pubmed: 17652507
J Aerosol Med Pulm Drug Deliv. 2013 Jun;26(3):157-64
pubmed: 23517172
Methods Mol Biol. 2012;842:49-66
pubmed: 22259129
PLoS One. 2013;8(3):e58658
pubmed: 23527003
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Nature. 2014 Jan 16;505(7483):412-6
pubmed: 24317696
Thorax. 2008 Feb;63(2):129-34
pubmed: 17675316
J Thorac Imaging. 2006 Mar;21(1):14-21
pubmed: 16538150
J Aerosol Med Pulm Drug Deliv. 2019 Aug;32(4):189-199
pubmed: 30964381
BMC Pulm Med. 2011 Sep 06;11:45
pubmed: 21896198
J Pediatr. 2014 Apr;164(4):839-45
pubmed: 24373575
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Pediatr Pulmonol. 2002 Jun;33(6):483-91
pubmed: 12001283
JCI Insight. 2018 Dec 20;3(24):
pubmed: 30568035
Am J Respir Crit Care Med. 2007 Apr 15;175(8):822-8
pubmed: 17234902
Cell. 1998 Dec 23;95(7):1005-15
pubmed: 9875854
Am J Respir Crit Care Med. 2005 Feb 1;171(3):249-56
pubmed: 15516530
J Allergy Clin Immunol. 1998 Apr;101(4 Pt 1):475-83
pubmed: 9564800
J Clin Invest. 2016 Jun 1;126(6):2367-71
pubmed: 27183390
Am J Respir Crit Care Med. 2019 Mar 15;199(6):715-727
pubmed: 30352166

Auteurs

Beth L Laube (BL)

Department of Pediatrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.

Kathryn A Carson (KA)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Christopher M Evans (CM)

Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.

Vanessa L Richardson (VL)

Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.

Gail Sharpless (G)

Department of Pediatrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.

Pamela L Zeitlin (PL)

Department of Pediatrics, National Jewish Health, Denver, Colorado.

Peter J Mogayzel (PJ)

Department of Pediatrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH